Aggregates in monoclonal antibody (mAb) therapeutics pose a significant risk to patients by increasing the potential of an immunogenic response and reducing efficacy. In contrast to other mAb impurities, aggregates are not efficiently removed by protein A chromatography. They are particularly challenging to separate from the monomeric protein since they have very similar isoelectric points and hydrophobicities.
Eshmuno® CP‑FT cation exchange (CEX) resin is specifically designed to provide efficient removal of mAb aggregates in the flow-through frontal chromatography mode of operation enabling loading capacities 10× higher than traditional bind/elute CEX chromatography. Eshmuno® CP‑FT resin facilitates greater manufacturing flexibility and process intensification while reducing the overall cost for the downstream purification of mAbs.
|Eshmuno® CP-FT resin provides:|
Using Eshmuno® CP‑FT resin for high loading flow-through CEX chromatography offers significant savings over conventional CEX bind/elute chromatography processes, e.g. significantly less resin and buffers are required.